C B Tara Moore
Overview
Explore the profile of C B Tara Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baran-Rachwalska P, Saffie-Siebert S, Moore C
Methods Mol Biol
. 2021 Apr;
2282:443-453.
PMID: 33928589
Drug delivery to the eye remains a real challenge due to the presence of ocular anatomical barriers and physiological protective mechanisms. The lack of effective siRNA delivery mechanism has hampered...
2.
Baran-Rachwalska P, Torabi-Pour N, Sutera F, Ahmed M, Thomas K, Nesbit M, et al.
J Control Release
. 2020 Jul;
326:192-202.
PMID: 32653503
The major unmet need and crucial challenge hampering the exciting potential of RNAi therapeutics in ophthalmology is to find an effective, safe and non-invasive means of delivering siRNA to the...
3.
Christie K, Robertson L, Conway C, Blighe K, DeDionisio L, Chao-Shern C, et al.
Mol Ther
. 2020 May;
28(8):1846-1857.
PMID: 32416058
CRISPR-Cas9 provides a tool to treat autosomal dominant disease by non-homologous end joining (NHEJ) gene disruption of the mutant allele. In order to discriminate between wild-type and mutant alleles, Streptococcus...
4.
Maurizi E, Schiroli D, Atkinson S, Mairs L, Courtney D, OHagan B, et al.
Exp Eye Res
. 2018 Oct;
179:75-92.
PMID: 30365943
Pterygium is a pathological proliferative condition of the ocular surface, characterised by formation of a highly vascularised, fibrous tissue arising from the limbus that invades the central cornea leading to...
5.
Moore C, Christie K, Marshall J, Nesbit M
Prog Retin Eye Res
. 2018 Jan;
65:147-165.
PMID: 29378321
The potential of personalised genome editing reaching the clinic has come to light due to advancements in the field of gene editing, namely the development of CRISPR/Cas9. The different mechanisms...
6.
Christie K, Courtney D, DeDionisio L, Chao Shern C, De Majumdar S, Mairs L, et al.
Sci Rep
. 2017 Nov;
7(1):16174.
PMID: 29170458
CRISPR/Cas9 holds immense potential to treat a range of genetic disorders. Allele-specific gene disruption induced by non-homologous end-joining (NHEJ) DNA repair offers a potential treatment option for autosomal dominant disease....
7.
Moore J, Schiroli D, Moore C
Biomed Res Int
. 2016 Oct;
2016:5062064.
PMID: 27689081
Corneal cross-linking is nowadays the most used strategy for the treatment of keratoconus and recently it has been exploited for an increasing number of different corneal pathologies, from other ectatic...
8.
Allen E, Courtney D, Atkinson S, Moore J, Mairs L, Poulsen E, et al.
Hum Mol Genet
. 2016 Jan;
25(6):1176-91.
PMID: 26758872
Meesmann epithelial corneal dystrophy (MECD) is a rare autosomal dominant disorder caused by dominant-negative mutations within the KRT3 or KRT12 genes, which encode the cytoskeletal protein keratins K3 and K12,...
9.
Ramji H, Moore J, Moore C, Shah S
Cont Lens Anterior Eye
. 2016 Jan;
39(2):160-6.
PMID: 26733054
Purpose: To optimise intraocular lens (IOL) power calculation techniques for a segmental multifocal IOL, LENTIS™ MPlus(®) (Oculentis GmbH, Berlin, Germany) and assess outcomes. Methods: A retrospective consecutive non-randomised case series...
10.
Courtney D, Poulsen E, Kennedy S, Moore J, Atkinson S, Maurizi E, et al.
Invest Ophthalmol Vis Sci
. 2015 Jul;
56(8):4653-61.
PMID: 26207300
Purpose: Transforming growth factor beta-induced (TGFBI)-related dystrophies constitute the most common heritable forms of corneal dystrophy worldwide. However, other than the underlying genotypes of these conditions, a limited knowledge exists...